Amylyx prices upsized 14,090,000-share follow-on at $35.5/share for $500.2 million gross proceeds
AMLX•Offering priced at $35.5 per share
Amylyx priced an upsized underwritten public offering of 14,090,000 common shares at $35.5 per share.
Gross proceeds are expected to be about $500.2 million before fees, excluding any exercise of the underwriters’ option.
Closing expected on or about Aug. 21, 2026
The offering is expected to close on or about Aug. 21, 2026, subject to customary closing conditions.
Underwriters have 30-day option for additional shares
The underwriters hold a 30-day option to buy up to 2,113,500 additional shares.
Proceeds earmarked for avexitide work and corporate purposes
Amylyx said net proceeds are earmarked for avexitide pre-commercial work, research and development, working capital, and general corporate purposes.
